Last reviewed · How we verify
Geographic atrophy secondary to age-related macular degeneration
Approved treatments
- AVACINCAPTAD PEGOL SODIUM
- Izervay · Astellas Pharma
Izervay works by binding to and inhibiting the activity of Complement C5, a protein involved in the immune response. - Avacincaptad · Aviceda Therapeutics, Inc.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Geographic atrophy secondary to age-related macular degeneration patent landscape — cliff calendar, originator estates, attackable patents
- Geographic atrophy secondary to age-related macular degeneration treatment landscape brief
- Geographic atrophy secondary to age-related macular degeneration treatment updates RSS
Frequently asked questions about Geographic atrophy secondary to age-related macular degeneration
What drugs treat Geographic atrophy secondary to age-related macular degeneration?
Tracked treatments include AVACINCAPTAD PEGOL SODIUM, Izervay, Avacincaptad.
What is the treatment for Geographic atrophy secondary to age-related macular degeneration?
Standard treatment for Geographic atrophy secondary to age-related macular degeneration includes AVACINCAPTAD PEGOL SODIUM, Izervay, Avacincaptad. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Geographic atrophy secondary to age-related macular degeneration patent cliff · Geographic atrophy secondary to age-related macular degeneration CI report
- Treatment: AVACINCAPTAD PEGOL SODIUM
- Treatment: Izervay · Astellas Pharma
- Treatment: Avacincaptad · Aviceda Therapeutics, Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing